Rite Aid Pharmacies encourages Washington residents to vaccinate themselves and their children amid increasing pertussis cases in the state, the company announced Monday. Read More »
St. Louis-based Centene Corp. on Monday announced the appointment of Ken Yamaguchi as executive vice president and chief medical officer. Read More »
With a few days left for New Yorkers without health insurance to enroll in a health care plan, the New York State of Health (NYSOH) yesterday announced a partnership with CVS/pharmacy to make more enrollment resources available before the April 30 special enrollment deadline. Read More »
Approximately 700 people gathered in Albany, New York's capital, on Tuesday to lobby for the Pharmacists Society of the State of New York's goals, one of which is to amend the state’s anti-mandatory mail order law. Read More »
Transparency Market Research recently published a new study evaluating the impact of automation systems on the global pharmacy market. Read More »
Keryx Biopharmaceuticals said on Tuesday that Greg Madison was appointed to the company´s board of directors. Madison joined Keryx in 2014 and serves as the company´s president and chief operating officer. He will transition into the role of CEO by the end of May. Read More »
Pharmacy Quality Alliance (PQA) formed a formal research partnership on Wednesday with AllazoHealth to study and improve industrywide standards for medication adherence metrics. Read More »
Pfizer, Inc. recently named ExceleraRX Corp. to its limited drug distribution network. Read More »
Novartis said on Friday that the U.S. Food and Drug Administration (FDA) granted priority review designation to LCZ696, a test drug for the treatment of heart failure with reduced ejection fraction (HFrEF). Read More »
Pfizer said on Friday that the U.S. Food and Drug Administration has agreed to review the New Drug Application (NDA) for ALO-02, an abuse-deterrent opioid for chronic pain. Read More »
Pfizer said on Wednesday that the U.S. Food and Drug Administration has accepted for review the supplemental New Drug Application (sNDA) for XELJANZ, a medication for treating moderate to severe chronic plaque psoriasis. Read More »
Alerts Sign-up
